Uncategorized
Ophthotech Completes Patient Recruitment of the Second Phase 3 Pivotal Trial of Fovista® Anti-PDGF Therapy in Combination with Lucentis® in Wet Age-Related Macular Degeneration
NEW YORK--(BUSINESS WIRE)--Ophthotech today announced the completion of patient recruitment for its second Phase 3 trial of Fovista® in combination with Lucentis® for the treatment of wet age-related macular degeneration.
